Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krupski

Showing results (381-390 of 393) with videos related to

Pageof 40
Sort By:
The Journal of Allergy and Clinical Immunology|January 17, 2020
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)Pui Y Lee, Erinn S Kellner, Yuelong Huang, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
The Journal of Urology|September 25, 2019
Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year FollowupVivek Venkatramani, Isildinha M Reis, Erik P Castle, et al.
Lancet (London, England)|July 7, 2018
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trialDipen J Parekh, Isildinha M Reis, Erik P Castle, et al.
Pageof 40

Showing results (381-390 of 393) with videos related to

Sort By:
Pageof 40
The Journal of Allergy and Clinical Immunology|January 17, 2020
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)Pui Y Lee, Erinn S Kellner, Yuelong Huang, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Blood Advances|March 1, 2023
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALLKevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Blood Advances|November 17, 2021
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapyVanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, et al.
Blood|September 15, 2016
Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factorsShernan G Holtan, Nandita Khera, John E Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2021
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium ReportLiora M Schultz, Christina Baggott, Snehit Prabhu, et al.
The Journal of Urology|September 25, 2019
Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year FollowupVivek Venkatramani, Isildinha M Reis, Erik P Castle, et al.
Lancet (London, England)|July 7, 2018
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trialDipen J Parekh, Isildinha M Reis, Erik P Castle, et al.
Pageof 40